Intuitive Surgical shares fell about 10% after Q2 2026 revenue rose 19% but guidance for da Vinci procedure growth wasn't raised, pushing ISRG below its 200-week moving average.

Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

Abbott Just Showed Its Growth Engine Has More Than One Cylinder

Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.

Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.

Can Abbott Stock Deliver on Its Second-Half Growth Promise?

Medtronic bought the pain company to expand in neuromodulation, one of its areas of strategic focus and investment.

Medtronic completes SPR Therapeutics acquisition

The new capital will enable completion of the multi-centre investigational device exemption trial, TURBO.

RapidPulse obtains funding for stroke aspiration system

Medtronic (NYSE:MDT) has completed its acquisition of SPR Therapeutics. The deal adds a minimally invasive, non opioid treatment option for chronic and acute pain to Medtronic's pain therapy portfolio. For investors watching Medtronic, this move expands the company's presence in pain care beyond its existing device lineup. SPR Therapeutics focuses on peripheral nerve stimulation, a therapy that fits into a broader push across healthcare to reduce reliance on opioid medications for pain...

Medtronic (MDT) Completes SPR Therapeutics Deal To Expand Non Opioid Pain Care

In May 2026, Medtronic voluntarily initiated a Class II recall of 590 Octopus 4 Tissue Stabilizer devices after discovering an assembly issue in the tubing configuration, with the US FDA now listing the action as an ongoing enforcement event affecting worldwide distribution. Around the same time, Medtronic’s fiscal Q3 2024 results exceeded earnings and revenue expectations, drawing attention to how the company balances quality-control challenges with operational and financial...

How Medtronic’s (MDT) Targeted Device Recall and Earnings Beat Have Changed Its Investment Story

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

Insider Name	Relation to Company	Shares Changed	Price	Transaction Date
KIIL HARRY SKIP	Officer	4,189	$0.34	Jun 8, 2026
MARTHA GEOFFREY S	Chief Executive Officer	94,963	$N/A	May 26, 2026
KIIL HARRY SKIP	Officer	15,195	$N/A	May 26, 2026
WALL BRETT A	Officer	26,907	$N/A	May 26, 2026
MARINARO MICHAEL	Officer	18,994	$N/A	May 26, 2026
WALTER MATTHEW R.	Officer	9,149	$N/A	May 26, 2026
BLOMQUIST DENISE L	Officer	1,712	$N/A	May 26, 2026
BLOMQUIST DENISE L	Officer	1,508	$N/A	Apr 27, 2026
LEE JOON SUP	Director	1,803	$N/A	Apr 27, 2026
NABEL ELIZABETH G	Director	2,111	$N/A	Apr 27, 2026

MDT(MDT)
NASDAQ

Company Profile & Information

Company Profile

Business Overview

Insider Transactions

Similar Companies

Analysis Tools

MDT(MDT)NASDAQ